Delavirdine (U 90152) is a potent, highly specific and orally active non-nucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine selectively inhibits HIV-1 reverse transcriptase (RT) (IC50=0.26 μM) over DNA polymerase α (IC50=440 μM) and polymerase δ (IC50>550 μM). Delavirdine is an inhibitor of HIV-1 replication and can can be used for the study of AIDs.

Eravacycline dihydrochloride is a potent and broad-spectrum antibacterial agent. It disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit and is bacteriostatic.

Iclaprim is a new selective bacterial Dihydrofolate inhibitor, which can inhibit the growth of S. aureus (MRSA) with an MIC90 of 0.06 μg/mL.

BQ-788 sodium salt is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC50 of 1.2 nM in human Girrardi heart cells.

Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively.

Necrostatin-2 is a potent inhibitor of necroptosis with an EC50 of 50 nM in FADD-deficient Jurkat T cells treated with TNF-α.

2′,5′-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor via binding the P-site with an IC50 of 3 µM . 2′,5′-Dideoxyadenosine is a nucleoside analog and exerts a potent antiadrenergic action in heart.

AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) […]

ATN-224 is a second-generation tetrathiomolybdate analogue and an orally active inhibitor of Cu2+/Zn2+-superoxide dismutase 1 (SOD1) with an IC50 of 17.5 nM. It inhibits angiogenesis and tumor growth and can be used in advanced solid and advanced hematologic malignancies research.

MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.